BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Not Applicable

Completed

Conditions: Contraception

Interventions: Device: ESS505 (BAY1454033)

First Posted Date: 2013-09-24

Last Posted Date: 2024-10-17

Lead Sponsor: Bayer

Target Recruit Count: 660

Registration Number: NCT01948882

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism
Atrial Fibrillation
Acute Coronary Syndrome

Interventions: Drug: Rivaroxoban (Xarelto, Bay59-7939)
Drug: Standard of care

First Posted Date: 2013-09-23

Last Posted Date: 2021-09-27

Lead Sponsor: Bayer

Target Recruit Count: 208958

Registration Number: NCT01947985

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Completed

Conditions: Pulmonary Embolism
Venous Thrombosis
Atrial Fibrillation
Acute Coronary Syndrome

Interventions: Drug: Rivaroxaban (Xarelto, Bay59-7939)
Drug: Warfarin
Drug: Antiplatelet drugs

First Posted Date: 2013-09-23

Last Posted Date: 2021-09-23

Lead Sponsor: Bayer

Target Recruit Count: 50299

Registration Number: NCT01947998

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism
Atrial Fibrillation
Acute Coronary Syndrome

Interventions: Drug: Rivaroxaban (Xarelto, Bay59-7939)
Drug: Standard of care

First Posted Date: 2013-09-23

Last Posted Date: 2021-10-22

Lead Sponsor: Bayer

Target Recruit Count: 665533

Registration Number: NCT01947959

Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo (treatment 1)
Drug: BAY1067197 (treatment 2)

First Posted Date: 2013-09-18

Last Posted Date: 2019-09-19

Lead Sponsor: Bayer

Target Recruit Count: 11

Registration Number: NCT01945606

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Phase 3

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: STW5 (Iberogast, BAY98-7411)

First Posted Date: 2013-09-12

Last Posted Date: 2018-10-29

Lead Sponsor: Bayer

Target Recruit Count: 243

Registration Number: NCT01940848

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

Phase 3

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Placebo

First Posted Date: 2013-09-11

Last Posted Date: 2017-10-20

Lead Sponsor: Bayer

Target Recruit Count: 25

Registration Number: NCT01939223

Locations: 🇬🇧
Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BAY1143572

First Posted Date: 2013-09-10

Last Posted Date: 2017-10-20

Lead Sponsor: Bayer

Target Recruit Count: 80

Registration Number: NCT01938638

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2013-09-04

Last Posted Date: 2018-03-26

Lead Sponsor: Bayer

Target Recruit Count: 45

Registration Number: NCT01934790

Regorafenib Post-marketing Surveillance in Japan

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2013-09-02

Last Posted Date: 2022-04-01

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT01933958

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy